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Summary
The regulation of the activity of Abl and Src family
tyrosine kinases is mediated by intramolecular in-
teractions between the SH3, SH2, and kinase (SH1)
domains. We have determined the crystal structure of
an unphosphorylated form of c-Src in which the SH2
domain is not bound to the C-terminal tail. This re-
sults in an open structure where the kinase domain
adopts an active conformation and the C terminus
binds within a hydrophobic pocket in the C-terminal
lobe. NMR binding studies support the hypothesis
that an N-terminal myristate could bind in this pocket,
as observed for Abl, suggesting that c-Src may also
be regulated by myristate binding. In addition, the
structure contains a des-methyl analog of the antileu-
kemia drug imatinib (STI571; Gleevec). This structure
reveals why the drug shows a low affinity for active
kinase conformations, contributing to its excellent ki-
nase selectivity profile.
Introduction
The BCR-ABL gene is the cause of chronic myeloge-
nous leukemia (CML), and some acute lymphoblastic
leukemias (ALL) (Sawyers, 1999). This oncogene encodes
the Bcr-Abl protein, which possesses a constitutively ac-
tivated Abl tyrosine kinase domain that abrogates the
growth factor requirements for the proliferation and
survival of hematopoietic cells by unregulated phos-
phorylation of cellular proteins (Deininger et al., 2000;
Faderl et al., 1999; Sawyers, 1999). The antileukemia
drug, imatinib, acts by selectively inhibiting the tyrosine
kinase activity of Bcr-Abl (Capdeville et al., 2002). Al-
though clinical responses to STI571 in patients with
stable-phase CML are durable (Hughes et al., 2003),
patients in late-stage disease frequently develop drug
resistance and relapse (Kantarjian et al., 2002). Relapse
is often associated with point mutations in the Bcr-Abl
kinase domain that reduce the affinity of imatinib (Gorre
et al., 2001; Cowan-Jacob et al., 2004; Hochhaus and
La Rosee, 2004). A possible approach to circumventing
patient relapse is to inhibit downstream signaling stim-
ulated by Bcr-Abl phosphorylation or block alternative
signaling pathways that lead to Ph+ cell survival. Inhibi-
tion of c-Src kinase activity could provide a combined*Correspondence: sandra.jacob@novartis.comstrategy for these approaches, as Bcr-Abl has been
shown to activate c-Src by phosphorylation and the
growth factor interleukin-3, which signals through the
c-Src pathway, has been shown to rescue Bcr-Abl-
expressing cells in the presence of antiproliferative
concentrations of STI571 (Warmuth et al., 2003).
Members of the c-Src-family of kinases all contain
SH3, SH2, and kinase (SH1) domains followed by a
short C-terminal regulation segment. Phosphorylation
of Tyr527 in the C-terminal tail is found to downregulate
the kinase activity, and phosphorylation of Tyr416 in the
activation loop is necessary for full kinase activity. One
or the other of the tyrosines in the cellular enzyme is
phosphorylated, but not both. Structures of both hu-
man and chicken c-Src (Williams et al., 1997; Xu et al.,
1997, 1999) phosphorylated on Tyr527 (chicken c-Src
numbering) revealed an autoinhibitory state of the pro-
tein, referred to as the “assembled regulatory domain”
conformation. There are several components of this as-
sembly that negatively regulate the activity of the ki-
nase domain. The position of helix αC, the conforma-
tion of the activation loop, and the configuration of the
remaining catalytic machinery, all in the kinase domain,
make a direct contribution because they are unsuitable
for activity. The binding of the SH3 domain to the linker
between the SH2 and kinase domains, and the binding
of the SH2 domain to p-Tyr527 on the C-terminal tail,
will inhibit the interaction of these domains with other
cellular proteins that have been shown to enhance the
activity of c-Src and may restrain the protein from
adopting a fully active conformation, but they will not
necessarily prevent some residual activity (Lerner and
Smithgall, 2002).
Although the N-terminal region of c-Abl contains a
similar arrangement of SH3, SH2, and kinase domains
that have a role in the regulation of the kinase activity,
it lacks a phosphorylation site equivalent to Tyr527 in
the c-Src family of tyrosine kinases. Recent structural
and functional studies (Pluk et al., 2002; Nagar et al.,
2003; Hantschel et al., 2003), have shown that at least
the 1a form of Abl contains an N-terminal myristyl mod-
ification, which is able to bind in a pocket located in
the C-terminal lobe of the kinase domain, thus locking
the protein into an autoinhibitory assembled conforma-
tion very similar to that of the c-Src and Hck structures
(Sicheri et al., 1997; Williams et al., 1997; Schindler et
al., 1999; Xu et al., 1997, 1999). The inactive conforma-
tion of the c-Src family kinase domains and that of
c-Abl are, however, significantly different (Schindler et
al., 2000; Nagar et al., 2003). This helps to explain why
STI571 binds strongly to c-Abl, but only very weakly to
c-Src, because it is known that STI571 has high affinity
for the specific inactive conformation of c-Abl, but very
low affinity for the active conformation of the kinase
(Schindler et al., 2000).
During the optimization of the Bcr-Abl kinase inhibi-
tory activity of STI571, the activity of the lead com-
pound 1 against c-Src was removed by incorporating a
methyl group (Figure 1). Reintroducing this activity into
the STI571 structure might therefore lead to com-
Structure
862Figure 1. Chemical Structures Referred to in
this Article and Details of the Binding of
Compound 2 to c-Src
(Top) The IC50 values for inhibition of trans-
phosphorylation by compound 2 and STI571
versus c-Src and Abl kinase are shown
in nanomolar concentrations (description of
measurements provided as Supplemental
Data).
(Bottom) Details of the binding of compound
2 (green) to c-Src (yellow) showing hydrogen
bonds with red dashed lines. The structure
of STI571 (magenta) as bound to Abl kinase
is superimposed.pounds that could be capable of circumventing STI571 t
tresistance in CML patients. Combined Abl-Src inhibi-
ptors have recently been described, and BMS-354825
vhas entered phase II clinical trials (O’hare et al., 2004;
rShah et al., 2004). In order to understand the structural
pbasis of why STI571 did not inhibit c-Src, we carried
cout structural biology studies with an analog of STI571,
2, which retained activity against c-Src. In addition to
Srevealing why STI571 does not strongly inhibit the ki-
Dnase activity of c-Src, the X-ray crystal structure of the
ccomplex between 2 and c-Src has revealed a new, par-
0tially assembled state of the protein in which the kinase
0domain adopts an active conformation.
s
aResults
s
uProtein Preparation 1
Human c-Src tyrosine kinase is a multidomain protein f
of 535 amino acids (Boggon and Eck, 2004). The full- p
length protein exhibits limited solubility and stability, i
making it unsuitable for structural studies. Mutants of m
c-Src lacking the N-terminal myristylation site and the s
“unique” domain, but including SH3, SH2, kinase do- t
main and C-terminal tail, have been described (Ellis, o
1994) and a construct with the N-terminal amino acids t
Gly1–Gly84 (human numbering) deleted has been suc- c
cessfully crystallized (Xu et al., 1997) when phosphory- o
lated at Tyr529 (Tyr527, chicken numbering) of the a
C-terminal tail. The amino acid numbering of chicken i
c-Src will be used subsequently here for consistency 3
with earlier publications. f
Expression of this c-Src construct in Sf9 cells led to w
a mixture of un-, mono-, and diphosphorylated forms,
the unphosphorylated form representing about one T
third of the total c-Src. Addition of a c-Src inhibitor to T
uthe cell culture at the time of viral infection increasedhe fraction of the unphosphorylated form to w70%;
he remainder of the expressed c-Src was monophos-
horylated. The two forms could be separated by con-
entional ion-exchange chromatography, which also
emoved the inhibitor and allowed subsequent recom-
lexation of the purified unphosphorylated c-Src with
ompound 2.
tructure Determination of Unphosphorylated c-Src
iffraction data were collected for a single crystal of
-Src in complex with compound 2, which grew to
.25 × 0.25 × 0.25 mm3 in size in 1.3 M (NH4)2SO4,
.1 M Tris (pH 8.0) and 12% glycerol (Table 1). The
tructure was solved using single domains of the
ssembled structure (PDB entry 2SRC) as individual
earch models in molecular replacement and refined
sing all data between 40.0 and 1.9 Å resolution (Table
). Electron density for compound 2 was clearly visible
rom the early stages of refinement, although only the
yridinyl, pyrimidinyl, and diaminophenyl rings of the
nhibitor are well defined (see Figure S1 in the Supple-
ental Data available with this article online). Weak re-
idual density for the remainder of the inhibitor was fit-
ed in the latter stages of refinement; however, the
ccupancy of this part of the inhibitor is low, reflecting
he fact that it is flexible and probably adopts multiple
onformations in the crystal. The final model consists
f residues 83–533 (chicken numbering) of c-Src plus
n N-terminal methionine (82), compound 2, five sulfate
ons that originate from the crystallization buffer, and
15 water molecules. The coordinates and structure
actors have been deposited in the protein data bank
ith PDB entries 1Y57 and 1Y57SF.
he Overall Structure of Unphosphorylated c-Src
he structures of the SH3, SH2, and kinase domains of
nphosphorylated c-Src resemble the published struc-
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863Table 1. Crystallographic Data Collection and Refinement Statistics
Data Collection Refinement
Space group P41212 R factor 0.188
Unit Cell dimensions (Å) a = b = 106.21; c = 123.73 R free 0.213
Solvent content (%) 64 (VM = 3.38 Å3/Da) Free R test size (no., %) 2813, 5.1
Molecules in the asymmetric unit (no.) 1 Protein residues and atoms (no.) 452, 3600
Resolution range (Å) (last shell) 40.0–1.90 (1.97–1.90) Heterogen atoms (no.) 36
Measured reflections (no.) 393,745 Solvent atoms (no.) 315
Unique reflections (no.) 55,642 Sulfate groups (no.) 5
Redundancy 7.1 Rmsd bond lengths (Å) 0.011
Completeness (%) 99.8 (99.6)a Rmsd bond angles (°) 1.25
Rsym (%)b 9.0 (43.5)a Average B factors (Å2) (overall, protein, 27.52, 30.09, 45.59,
inhibitor, water, sulfate) 45.14, 65.75
% reflections with I/Sig(I) > 2 80.2 (43.1)a
a Values presented are overall resolution, with values in parentheses being from highest resolution shell.
b Rsym = Σ | I − <I> |/Σ I, where I is the observed intensity of a reflection and <I> is the average intensity of multiple observations of symmetry-
related reflections.tures of the individual domains (Waksman et al., 1992;
Feng et al., 1994) and those of the assembled inactive
state (Xu et al., 1997, 1999). However, the lack of phos-
phorylation of Tyr527 means that the SH2 domain is not
locked down beside the C-terminal lobe of the kinase
domain in the crystals. The SH3 and SH2 domains are
found to lie approximately at right angles to the kinase
domain with only the SH3 domain and linker in contact
with the N-terminal lobe, where they stack alongside
helix αC (Figure 2). The SH3 domain is bound to the
linker between the SH2 domain and the kinase domain,
as observed in the assembled inactive conformation
(Xu et al., 1999). The SH2 domain binding site contains
sulfate ions from the crystallization buffer and water
molecules. The unphosphorylated C-terminal tail is well
defined in the electron density and folds back into the Lys343 in the hinge, Met314 in αC, and Val323 of the
Figure 2. Conformational States of c-Src
Comparison of the structures of human c-Src phosphorylated on Tyr527 (left) and in the unphosphorylated state (right). Both structures have
the same orientation with respect to their C-terminal lobes, which were superimposed. The ribbon diagrams are colored from dark blue at
the N terminus to red at the C terminus; thus, the SH3 domain is blue, the SH2 domain is light blue and green, the linker is aqua, the N-terminal
lobe is green, the C-terminal lobe is light green and orange, the activation loop is yellow, and the C-terminal tail is red. The ligands (magenta),
sulfate groups (yellow and red), and certain side chains (yellow) discussed in the text are also represented.C-terminal lobe of the kinase domain, where it be-
comes an integral part of the structure. In fact, the
C-terminal leucine is found to bind in a pocket that is
used by myristate in the assembled inactive conforma-
tion of c-Abl (Nagar et al., 2003) (Figure 3). The kinase
domain itself has undergone significant conformational
changes, and helix αC now occupies the position that
is observed for active kinases. The activation loop does
not block the active site and has an extended confor-
mation that also resembles an active kinase, although
phosphorylation of Tyr416 would be required for the
loop to form a suitable platform for the binding of sub-
strate. The N- and C-terminal lobes of the kinase have
rotated away from each other by approximately 13°
(through an axis passing close to the Cα positions of
Structure
864Figure 3. The Potential Myristate Binding Pocket
(Top) Superposition of the unphosphorylated c-Src structure (green) with the structure of the myristate bound c-Abl (PDB accession code
1OPJ, cyan), showing the path of the phosphorylated C-terminal tail of pTyr527 c-Src in yellow. Solvent-accessible surfaces are superimposed
for: unphosphorylated c-Src calculated excluding the C-terminal tail (left), Abl kinase (middle), and pTyr527 c-Src (right). The Tyr527 side
chain of unphosphorylated c-Src is shielded by Pro529, and Leu533 binds in the upper half of the pocket with respect to myristate.
(Bottom) Sequence alignment comparing the C-terminal regions of the Src-family kinases and that of Abl, plus other residues lining the
potential myristate binding pocket (E, entrance; M, middle; B, bottom of pocket; #, tyr527; *, strictly conserved; :, conservative substitutions).αC-β4 loop), leaving more space in the cleft between a
ethem, which is required for the binding of compound 2.
b
wInhibitor Binding
Compound 2 binds in the adenine binding site of ATP, r
kmaking two hydrogen bonds to Met341 of the hinge
region between the two lobes in a similar fashion to
that of many kinase inhibitors (Figure 1). The pyridinyl, S
Tpyrimidine, and diaminophenyl groups are well defined
in the electron density, although the exact orientation c
sof the pyridinyl ring can not be defined due to the lack
of hydrogen bonds that would indicate the position of t
bthe nitrogen atom. The rest of the inhibitor lies close to
the ribose binding site of ATP, but is largely exposed to o
1solvent. The three rings in the adenine binding site are
coplanar. Other residues lining the binding site include: t
iLeu273, Gly274, Gln275, and Val281 from the glycine-
rich or P loop, Ala293 from β3 of the N-terminal lobe, f
aGlu339 and Tyr340 from the hinge region, and Leu393
from the N-terminal part of the activation loop. m
SThis mode of binding is clearly different from that ob-
served for STI571 to c-Abl (Figure 1). The presence of a
othe 6-methyl group on the diaminophenyl ring means
that a noncoplanar conformation of the diarylamine s
Fmoiety is preferred in STI571. This is the conformation
that is required for STI571 to bind to the inactive con- t
oformation of c-Abl (Schindler et al., 2000). Assuming
that c-Src cannot adopt the same inactive conforma- s
stion as observed for c-Abl (Nagar et al., 2002), despite
the high sequence identity between the two kinases, in c
dorder for STI571 to bind to c-Src it would have to adopt
a coplanar arrangement of the pyridinyl, pyrimidinyl, And diaminophenyl rings, and furthermore, the pres-
nce of the methyl group would weaken the hydrogen
onds to the hinge region of c-Src due to steric clashes
ith main chain atoms of Met341 and Ser342. This has
ecently been observed for STI571 in complex with Syk
inase (Atwell et al., 2004).
H2 and SH3 Domain Structure
he SH3 and SH2 domains are rotated by about 130°
ompared to their position in the assembled inactive
tate; however, they have retained the “clamp” struc-
ure (Harrison, 2003), in which the SH3 domain remains
ound to the linker. Although the individual structures
f the domains have changed very little (rmsd values of
.1 and 0.7 Å for the SH3 and SH2 domains, respec-
ively), the relative angle between the two domains has
ncreased by about 25°, resulting in a shift of up to 12 Å
or residues of the SH2 domain when the SH3 domains
re superimposed (Figure 4). The hinge region for this
otion lies between the SH3 and SH2 domains, near
er140, and also involves residues from the linker
round Thr247. This flexibility has previously been rec-
gnized by comparing solution (NMR) and crystal
tructures of SH3-SH2 domains from proteins such as
yn, Lck, Abl, and c-Src (Ulmer et al., 2002) compared
o all the other structures and the open conformation
bserved here. The conformation adopted in the as-
embled inactive state of c-Src is closed. The actual
tructure of the residues in the hinge region has
hanged very little (Figure 4), except that Ser140 un-
ergoes a peptide plane flip of 180°, and, along with
sp141, it makes hydrogen bonds to the main chain of
Active Conformation of c-Src
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(Left) Superposition of the SH3 and SH2 domains and the linkers from the assembled inactive (dark-blue, red, and magenta) and the unphos-
phorylated (cyan, green, and yellow) structures, respectively. The superposition is based on residues from the SH3 domain only (84–142) and
is viewed from the same orientation as in Figure 2 in order to show how the clamp opens up on release from pTyr527.
(Right) Stereo view of the connector region showing important hydrogen bonds (orange) for unphosphorylated c-Src (green) and pTyr527
c-Src (magenta).residue Met82, which is not seen in the phosphorylated
structures (Xu et al., 1997, 1999).
The binding sites of both of the SH domains are oc-
cupied in this structure. That of the SH3 domain is oc-
cupied by the linker as in the autoinhibited structure,
and the phosphotyrosine binding site of the SH2 do-
main is occupied by a sulfate ion, that arises from the
crystallization buffer. This sulfate lies in a very similar
position to the phosphate of other SH2-phosphotyro-
sine complexes, but in quite a different position to the
phosphate of the assembled inactive structure of c-Src
(PDB entry 2SRC), which reflects the poor binding of
the C-terminal tail of c-Src in the latter structure. In the
structure of assembled inactive Hck (Schindler et al.,
1999), where the C-terminal tail has been modified to
resemble a high-affinity SH2 ligand, the phosphate su-
perimposes well with the sulfate observed here. The
rest of the binding site, which is not significantly dif-
ferent as there are only slight shifts in the positions of
side chains Arg155, Arg156, Glu178, and Lys203, is oc-
cupied by water molecules, and there are also two
more sulfate ions in the vicinity.
The SH2-Kinase Linker
The structure of the linker region is also similar to that
of the inactive conformation (Figure 4). It superimposes
well for the region 245–248 when the SH2 domains are
used for the alignment and for the region 250–254 using
the SH3 domains are used for alignment. Residues
247–249, where the linker kinks to allow opening of the
angle between the two domains, are also the ones that
have the highest B values in the linker. The end of the
linker beyond the SH3 binding site adopts a different
conformation starting from Ala256. Actually, the back-
bone carbonyl of Leu255 is flipped by 180° so that the
linker region can continue in an extended conformation
up to Ala259, where residues 258–261 form a β turn that
allows Tyr260 to pack against Lys315 from helix αC.
This conformation is stabilized in the unphosphorylatedc-Src structure by hydrogen bonds between Asp258
and Lys315, the backbone NHs of Trp260 and Glu97,
and via a water molecule to Glu261. Further stabiliza-
tion comes from the hydrogen bond between Glu97 and
Trp260. In the monophsophorylated structure, Asp258
faces the solvent.
Conformational Changes in the Kinase Domain
A comparison of the structure of unphosphorylated
c-Src with that of the closely related Lck kinase domain
in the activated state (Yamaguchi and Hendrickson,
1996) (Figure 5), shows that it adopts an active confor-
mation. Although the Lck structure is of an isolated ki-
nase domain, the orientation of the Lck N terminus su-
perimposes well with the end of the SH2-kinase linker
of unphosphorylated c-Src reported here, but it is quite
different from the orientation in the assembled inactive
state of c-Src. This suggests that the orientation of the
SH3 and SH2 domains relative to the kinase domain is
determined by the few residues, including Trp260 and
Glu261, at the end of the linker region.
The conformation of the activation loop in unphos-
phorylated c-Src is extended, similar to the conforma-
tion of this loop in other active kinases, although it does
not adopt the same conformation as it probably would
in the phosphorylated state (Figure 5). Phosphorylation
of Tyr394 in Lck allows the loop to adopt a conforma-
tion suitable for the binding of substrate. This confor-
mation is stabilized by Arg387 (409 in c-Src), Arg363
(385), Ala396 (418) and, possibly, Arg397 (419), all of
which coordinate and/or stack against the phosphory-
lated tyrosine. In the unphosphorylated c-Src structure
presented here, the N-terminal part of the activation
loop superimposes very well with that of activated Lck
(rmsd. of 8 Cα atoms is 0.21 Å). This region, along with
helix αEF and the αEF-αF loop, form the surface against
which the remainder of the activation loop (411–424)
folds. Arg409 forms a cation-aromatic interaction with
the unphosphorylated Tyr416, and would shift to make
Structure
866Figure 5. Active Kinase Conformations
(Left) Superposition of activated Lck (gray) and unphosphorylated c-Src (green). The activation loop, the αC helix, the glycine-rich loop and
the C-terminal tail of c-Src are colored magenta, red, blue, and yellow, respectively. The Trp260, Lys295, Glu310 and Leu533 side chains are
also shown in yellow (c-Src) and cyan (Lck, PDB entry 1QPC). Trp260 of c-Src has the same conformation as in the Lck staurosporine
complex (PDB entry 1QPJ, not shown).
(Right) Superpostion of the activation loops of unphosphorylated c-Src (green), pTyr527 c-Src (yellow), and activated Lck (gray). The substrate
as bound to activated Irk (magenta) is also shown.room for the phosphorylated side chain. Tyr416 also f
whas van der Waals interactions with Ala418 and a close
contact between the hydroxyl oxygen and Arg385-NH1 C
P(3.2 Å), but no other stabilizing interactions, which is
reflected in the relatively high B values of this part of i
the activation loop. Presumably, the gain of activity on i
phosphorylation of c-Src Tyr416, as observed for other z
kinases (Russo et al., 1996), is due to reconstitution of H
the substrate binding site, as well as stabilization of the
conformation of catalytic residues in the active site. a
The locations of the catalytic residues of c-Src in the 2
unphosphorylated state are also very similar to those t
of activated insulin receptor kinase (Irk) in complex with m
AMP-PNP (Hubbard, 1997). The structural features re- (
quired for activity are therefore conserved, even though s
the activation loop of c-Src is not phosphorylated. In p
addition to the catalytic residues (such as Asp386 and s
Asn391), the DFG motif (residues 404–406), and the salt q
bridge (Lys295–Glu310) all superimpose with the equiv- t
alent residues in activated Lck and activated Irk. In c
the monophosphorylated, autoinhibited c-Src struc- c
ture, the positions of all of these residues are incompat- r
ible with activity (Xu et al., 1999). t
A
tThe C-Terminal Tail and Myristate Binding
rThe C-terminal leucine binds in a pocket lined with resi-
tdues from the turn between αD and αE, the end of helix
sαF and the start of helix αH (Figures 2 and 3). The car-
sboxy terminus has hydrogen bond interactions with the
hbackbone nitrogens of Leu360 and Gly530, and the hy-
ldroxyl group of Tyr527. The latter interaction is stabi-
flized by the stacking of Tyr527 against Pro529, which
is conserved in all members of the Src family kinases
except Hck, Lyn, and Blk (Figure 3). This interaction ef- tectively shields the tyrosine from phosphorylation,
hich would lead to inactivation of the kinase. The
-terminal tail is shorter for Hck, Lyn, Lck, and Blk, and
ro529 is not strictly conserved in these kinases. If this
nteraction occurs in Lck, it would not have been seen
n the structures because the protein used for crystalli-
ation is truncated at the C terminus (Yamaguchi and
endrickson, 1996).
The myristate binding site is used as a “lock” in the
ssembled inactive conformation of c-Abl (Nagar et al.,
003) (terminology from Harrison, 2003). Because all of
he Src family kinases require myristylation at the N ter-
inus for membrane association and biological activity
Resh, 1994), it is possible that this pocket could also
erve as a myristate binding site when Tyr527 is phos-
horylated. A comparison of the Abl and c-Src pockets
hows that the sequence homology is high and the re-
uired conformational changes are slight (Figure 3). At
he bottom of the pocket, the increase in size of the
-Src side chain Leu491 compared to Abl Val487 is
ompensated by a decrease in size of the opposing
esidue in c-Src (Val364) compared to Abl (Leu360). In
he middle of the pocket, c-Src Leu360 is larger than
bl Ala356, but in the absence of the C-terminal
ail, there is ample room for the Leu side chain to
otate and leave the pocket open. When comparing
he monophosphorylated and unphosphorylated c-Src
tructures, at the mouth of the pocket, the observed
hift of the end of the loop connecting helix αG and
elix αH (up to 0.8 Å), with similar magnitudes in the
oop between helices αD and αE, shows that there is
lexibility to allow for the binding of other ligands.
NMR experiments with unphosphorylated c-Src in
he presence of myristate clearly showed no interaction
Active Conformation of c-Src
867Figure 6. NMR Spectra for Unphosphorylated and Phosphorylated c-Src in Complex with Compound 2
NMR spectra for unphosphorylated and phosphorylated c-Src in complex with compound 2, in the presence (blue) and absence (black)
of myristate.
(Top panel) The difference spectrum (red) shows sharp myristate signals in the presence of unphosphorylated c-Src, indicating that myristate
is tumbling independently and is not interacting with the protein.
(Bottom panel) In the case of phosphorylated c-Src, however, the difference spectrum shows peaks due to chemical shift changes of the
protein. In addition, the signals for the fatty acid have become invisible, indicating that myristate interacts with c-Src and thus adopts the
broad lines of the protein.of this fatty acid with the protein (Figure 6). However,
after incubation of c-Src with ATP in the presence of
C-terminal Src kinase, which is known to phosphorylate
Tyr527 (Okada and Nakagawa, 1989), a phosphorylated
form of c-Src was obtained that displayed clear spec-
tral differences in the presence and absence of myris-
tate, indicating myristate binding to the protein (Figure
6). Although these results do not indicate the site of
binding, the fact that myristate binding is only observed
with the phosphorylated protein is consistent with the
idea that the Leu533 binding site would be liberated by
phosphorylation of Tyr527.
Discussion
Comparison of STI571 and Compound 2 Binding
Modes to c-Src and Abl
STI571 stabilizes an autoinhibited state of Abl kinase,
requiring the shift of the absolutely conserved DFG mo-
tif at the N terminus of the activation loop to bind. The
structure reported here shows that the binding mode of
compound 2 to c-Src is quite different from that of
STI571 bound to Abl (Figure 1), but it is similar to the
observed binding mode of STI571 to Syk (Atwell et al.,
2004). The coplanar conformation of the pyridinyl, pyri-
midinyl, and diaminophenyl groups is less favorable for
STI571 due to steric clashes involving the methyl sub-
stituent of the diaminophenyl group. However, there is
no obvious structural reason why STI571 and 2 cannot
bind to c-Src with the STI571 binding mode. From this
we can speculate that c-Src is not able to adopt thesame autoinhibited conformation that is stabilized in
Abl kinase by the binding of STI571. The structures of
assembled inactive c-Src and Abl (containing SH3,
SH2, and kinase domains) (Xu et al., 1999; Nagar et al.,
2003), and the isolated Abl kinase domain (Nagar et al.,
2002; Cowan-Jacob et al., 2004), show distinct inactive
conformations, supporting this speculation. The con-
formation of the DFG motif in the assembled inactive
Abl structure is different from both the conformation
required for activity and that stabilized by the binding
of STI571, whereas the rest of the kinase domain
adopts an active conformation. STI571 cannot bind to
this assembled inactive state without inducing confor-
mational changes, which is reflected in the observed
affinity of 400 nM compared to 150 nM for the inactive
kinase domain (Hantschel et al., 2003). Neither of these
conformations has been observed for the c-Src kinase
domain. The elements of kinase sequences that con-
tribute to this restriction have yet to be identified.
Regulation and Activation of c-Src
The structure of cSrc reported here shows an active
conformation of the kinase domain despite the lack of
phosphorylation of Tyr416 in the activation loop. In cells
c-Src is found to be phosphorylated either on Tyr416
(active) or on Tyr527 (inactive), and the unphosphory-
lated state has not been observed. It is therefore pos-
sible that this conformational state has little relevance
to what occurs within the cell, and that it may even be
induced or stabilized by the presence of the inhibitor.
We have also obtained crystal structures of c-Src in the
Structure
868Figure 7. Schematic Diagram Showing a
Speculative Model for the Possible Initial
Steps in the Activation of c-Src Kinase
Based on the Structure of the Unphosphory-
lated Form and NMR Binding Studies
(Left) The assembled inactive state of c-Src
may involve myristate binding to the C-ter-
minal lobe of the kinase (yellow).
(Middle) Myristate binding to the membrane
could be the first step in the activation of
the kinase.
(Right) Unlatching of the SH2 domain and
opening up of the structure makes Tyr416
more accessible for phosphorylation. This is
the state observed in the crystal structure re-
ported here.apo form, with the ATP mimic, AMP-PNP, bound and r
awith other inhibitors (G. Rummel and S.W.C.-J., unpub-
lished data), suggesting that it is not dependent on the i
vtype of ligand bound and that it is compatible with the
binding of the natural cofactor. The conformation may s
lof course be stabilized by crystal contacts, but would
have to exist in solution in order for the crystals to form. t
tThis c-Src structure shows similarities to that of
Cdk2. Upon binding of cyclin, the αC helix of Cdk2 d
Sswings back into the active site, the residues required
for catalysis adopt an active conformation, and subse- a
wquent phosphorylation gives full activity (Jeffrey et al.,
1995; Russo et al., 1996). The SH3 domain seems to t
Tperform a similar action in c-Src. However, the relative
orientations of helix αC and the SH3 domain are also t
vfavored by the repositioning of Trp260 and surrounding
residues. The activation of c-Src observed when the e
pSH3 domain is displaced from the linker by binding to
an SH3 ligand (Moarefi et al., 1997; Lerner and Smith- A
agall, 2002) suggests that the presence of the SH3 do-
main next to helix αC is not necessary for the active m
Nconformation. The role of the C-terminal end of the
linker in the assembled inactive state may be to pin t
Trp260 between helix αC and the N lobe β sheet, where
it keeps the helix in the inactive or “out” position. Un- t
dpinning would occur with the release of the SH3-SH2-
linker clamp, so that Trp260 would be free to adopt the w
Hconformation observed both here and in the isolated
kinase domain of the activated Lck structure (Yama- o
Sguchi and Hendrickson, 1996), where it and Glu261 lie
at the surface of the protein and do not have a direct f
Tinfluence on the positions of secondary structure ele-
ments in the kinase domain. The fact that mutation of r
cTrp260 to alanine has been shown to activate Hck (La-
Fevre-Bernt et al., 1998), supports this theory. (
tThe structure of unphosphorylated c-Src lends evi-
dence to the “snap-lock” mechanism of kinase autoin- c
lhibition (Young et al., 2001), where residues in the SH3-
SH2 connector adopt a rigid structure when the two f
ldomains are bound to their internal docking sites. This
rigidity impedes the activating transition of the kinase. s
tRelease of the SH2 domain from pTyr527 leaves the
SH3 domain-linker interaction intact, but the structure I
fshows that there is flexibility between the two domains,
which also involves the linker. Solution and modeling
bstudies have also shown that the flexibility of the SH3-
SH2 connector increases when the two domains are (eleased from the assembled inactive state (Young et
l., 2001; Ulmer et al., 2002), and mutation of residues
n the connector to glycine leads to constitutative acti-
ation of c-Src (Young et al., 2001). All of these findings
uggest that any event that results in release of the snap-
ock will lead to activation of the kinase. Known activa-
ion mechanisms of Src-family kinases (dephosphoryla-
ion of the tail, displacement of the tail from the SH2
omain, SH3 domain displacement, mutations in the
H3-SH2 connector, mutations in the SH2-kinase linker,
nd binding of the kinase N lobe to other proteins)
ould be expected to cause conformational changes
hat destabilize the SH3-SH2 linker, therefore allowing
yr416 to be more accessible for phosphorylation and
hus full activation of the kinase. Any event that pre-
ents the snap-lock falling into place, could shift the
quilibrium toward the active conformation. For exam-
le, the binding of 2, which requires a larger cleft than
MP-PNP, or the mutation Thr338Ile observed in the
denine site of oncogenic v-Src (Kato et al., 1986),
ight both favor an opening of the angle between the
- and C-terminal lobes. This could explain the consti-
utive activation of the latter.
All of these regulation mechanisms support the idea
hat the mode of activation predetermines the type of
ownstream signaling that will occur. This hypothesis
as put forward based on studies that showed that
ck could be activated by an SH3-specific ligand with-
ut tail-release from the SH2 domain (Lerner and
mithgall, 2002), suggesting that SH3-based activation
avors signaling that does not involve the SH2 domain.
he crystal structure of the isolated Lck SH domains
eveals a conformation in which, due to a change in
onformation of residues in the SH3-SH2 interface
Asn120, Ser121) relative to other SH tandem struc-
ures, the SH3 domain is flipped away from the relative
-Src position by 140°. This type of flexibility would
eave room for interaction with SH3 ligands without af-
ecting the rest of the assembled state, although the
atter is likely to be more labile. The c-Src structure pre-
ented here shows that in the unphosphorylated state
he SH2 domain is available for downstream signaling.
n both cases phosphorylation of Tyr416 is required for
ull activity.
The observation that the C-terminal tail is found to
ind in a pocket equivalent to the Abl myristate site
Nagar et al., 2003) suggests that Src-family kinases
Active Conformation of c-Src
869could also be regulated by myristate binding. We have
shown that myristate binds to phosphorylated c-Src,
but not to the unphosphorylated form, which could be
explained by the blocking of the binding site by Leu533
in the latter case. In cells, if the N-terminal myristate
was bound in this pocket, the C-terminal Leu533would
be displaced, and Tyr527 would be exposed for phos-
phorylation, thereby favoring the adoption of the as-
sembled inactive state (Figure 7). Binding of the my-
ristyl group to the membrane would therefore be
necessary for activation, as has been observed pre-
viously (Resh, 1994). Experimental evidence needs to
be obtained to show whether myristate binding to the
kinase domain of c-Src actually has a role in regulation
and also to confirm the site of myristate binding. To this
end, residues in the C-terminal tail binding pocket
could be mutated, which would allow experiments to
determine if tail binding really protects Tyr527 from
phosphorylation in the wild-type protein compared to
the mutant. In addition, NMR spectroscopy could be
employed to see if the binding of myristate is abol-
ished. Cocrystallization of myristate with pTyr527 c-Src
would also be a possibility to confirm the binding site.
c-Src is necessarily a tightly regulated protein due to
its ubiquitous distribution and the fact that deregulation
leads to oncogenic behavior because of changes in cell
growth control, gene expression, metabolism, and cy-
toskeletal architecture; an extra form of regulation
would not be unjustified. One can also speculate that
other members of the Src family of kinases could be
regulated by myristate binding, because, although the
homology of the N-terminal unique region is low, the
length of this region is very similar to that of Abl kinase
and they are all N-terminally myristoylated or palmito-
ylated. Although the slightly shorter C terminus of the
Hck, Lck, Lyn, and Blk kinases means that the C-ter-
minal tail would not be able to bind to the potential
myristate binding pocket in the same way as for c-Src
kinase, the residues lining the pocket share high homol-
ogy (Figure 3).
Experimental Procedures
Preparation of Compound 2
4-[(4-Methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyri-
midinyl]amino]phenyl]-benzamide was prepared by 1,3-addition
of (3-nitrophenyl)guanidine to 3-(dimethylamino)-1-(3-pyridinyl)-2-pro-
pen-1-one, followed by Pd-catalyzed hydrogenation and amidation
of the resulting aniline with 4-[(4-methyl-1-piperazinyl)methyl]ben-
zoic acid (Sairam et al., 2003). The product was purified by column
chromatography (silica gel; eluent NH3 (25% aq.)-MeOH-CH2Cl2
(1:9:90) followed by recrystallization from EtOAc; melting point,
204°C–208°C).
Preparation of the ATP-Sepharose Column
Adenosine-5#-(γ-4-aminophenyl) triphosphate was synthesized ac-
cording to a published procedure (Haystead et al., 1993). A total
of 0.5 g of the ATP derivative was coupled to 6 g CNBr-activated
Sepharose 4B without spacer atoms (Amersham Biosciences) in
0.1 M NaHCO3 buffer for 1.5 hr at room temperature according to
the manufacturer’s instructions.
Protein Expression and Purification for Structural Studies
A recombinant baculovirus carrying the gene for a deletional mu-
tant of human c-Src (M/G1-G84/V85-L535, human numbering)
was kindly provided by M. Eck (Dana-Farber Cancer Institute). Ex-
pression in Sf9 cells was carried out in an 8 liter bioreactor (Fair-MenTec GmbH, Germany) in Excell 400 medium + 5% FCS at 28°C.
200 ml of recombinant baculovirus was added to the culture along
with a c-Src inhibitor in 500 ml of TC100 medium with 10% FCS, to
give a final inhibitor concentration of 5 M. After 72 hr, cells were
harvested by centrifugation and the pellet was stored at −70°C.
The cell pellet was lysed by sonication in buffer A (20 mM Tris, 5
vol % glycerol, 3 mM DTT [pH 8]) supplemented with additional 2
mM DTT and a protease inhibitor cocktail (Complete, Roche) and
the lysate clarified by centrifugation at 45,000 × g. The supernatant
was adjusted to pH 8.4 and applied in two portions to a 55 ml
column of Source 30 Q equipped with a 15 ml precolumn of SP-
sepharose FF. After a wash with buffer A, the precolumn was dis-
connected and c-Src eluted with a gradient to 200 mM NaCl. After
addition of 1 mM EDTA, c-Src-containing fractions were concen-
trated, NaCl and MgCl2 were added to 300 and 10 mM final con-
centrations, respectively, and the solution was applied to a 20 ml
column of ATP-Sepharose equilibrated with 0.3 M NaCl and 10 mM
MgCl2 in buffer B (20 mM HEPES, 5 vol % glycerol, 3 mM DTT, [pH
7.6]). After washing with equilibration buffer, c-Src was eluted with
0.9 M NaCl in buffer B, diluted with an equal volume of buffer B,
concentrated, and passed over two HiPrep 26/10 desalting col-
umns connected in series and equilibrated with 120 mM NaCl, 1
mM EDTA in buffer A. Unphoshorylated and monophosphorylated
c-Src were separated on a Mono Q HR10/10 column with a gradi-
ent from 40 to 280 mM NaCl in buffer A. Unphoshorylated c-Src
was applied to a HiLoad 16/60 Superdex 200 column and eluted
with 20 mM HEPES, 0.2 M NaCl, 0.2 mM EDTA, 3 mM DTT (pH 7.8).
Compound 2 (10 mM in DMSO) was added to a 3-fold molar ex-
cess, DTT was increased to 5 mM, and c-Src was concentrated to
15 mg/ml. The concentrated protein was either used immediately
for crystallization or aliquoted and stored at −80°C. All purification
steps were performed at 4°C and were analyzed by HPLC and SDS-
PAGE. Columns and resins used for chromatography were ob-
tained from Amersham Biosciences. c-Src was characterized by
LC-MS and N-terminal sequence analysis. Seventy percent of the
isolated c-Src was unphosphorylated, 30% was monophosphory-
lated, and about 15% of both forms had no N-terminal Met residue.
The final yield of purified unphosphorylated c-Src was 21 mg. The
molar ratio of compound 2 to c-Src was calculated from the HPLC
peak areas.
Crystallization and Data Collection
Crystallization screens were performed in 96-well sitting drop
plates (Corning): 0.8 l of protein at 15 mg/ml in 20 mM HEPES,
200 mM NaCl, 0.2 mM EDTA (pH 7.8 with 5 mM DTT) was mixed
with 1.0 l of screening solution and equilibrated with 100 l of the
screening solution. The protein solution contained a 1:1 molar ratio
of unphosphorylated c-Src and compound 2. Optimization was
performed in 24-well hanging drop vapor diffusion trays at room
temperature. For data collection, crystals grown with 1.3 M ammo-
nium sulfate, 0.1 M Tris (pH 8.0), and 12% glycerol were transferred
to the same buffer containing 25% glycerol before direct cooling in
the cryo-stream (Oxford Cryosystems Ltd, Oxford, UK) at 100 K.
The raw diffraction data were processed with Denzo and Scalepack
(HKL Research Inc., Charlottesville, VA).
Structure Determination and Analysis
The structure was determined using tools in the CCP4 graphical
user interface (CCP4, 1994) with the automated molecular replace-
ment script MOLREP (Vagin and Teplyakov, 1997). Rigid body re-
finement of the initial solution was performed with REFMAC5 (Mur-
shudov et al., 1997), before automatic refinement with all of the
data using ARP/wARP (Perrakis et al., 1997). Improvement of the
model then proceeded with cycles of model building on a Silicon
Graphics Inc. Octane with the program O (Jones et al., 1991) and
maximum likelihood refinement with REFMAC5. Individual temper-
ature factors were refined, and a bulk solvent correction was used
in scaling. Water molecules were added in the latter cycles of re-
finement using ARP/wARP. Structure comparisons were performed
using the program O, analysis of the quality of the model with PRO-
CHECK (Laskowski et al., 1993), and preparation of the images with
Molscript (Kraulis, 1991), O, and Molray (Harris and Jones, 2001) or
WebLab viewer Lite (Accelrys Inc. USA).
Structure
870Preparation of Phosphorylated c-Src Kinase for NMR F
TSpectroscopic Measurements
Unphosphorylated cSrc purified for crystallography, as described, v
2and complexed with compound 2 was exchanged into 20 mM Tris-
D11, 200 mM NaCl, 0.3 mM EDTA-D12, 3 mM DTT-D10 (pH 7.6). 2 G
mg c-Src in 1.5 ml of the deuterated buffer was phosphorylated by R
addition of 5 mM MgCl2, 0.16 mM ATP, and 40 l CSK at 4°C for 14 c
hr. The reaction was concentrated to 100 M c-Src and used with- t
out further purification. Analysis by LC-MS showed that 67% of
H
c-Src was monophosphorylated, 12% diphosphorylated, and 21%
K
unphosphorylated. C-terminal c-Src kinase (CSK) from rat spleen
s
was a kind gift of Prof. L.A. Pinna, University of Padova, Italy.
H
ONMR Spectroscopy of Unphosphorylated
5and Phosphorylated c-Src
HNMR spectroscopy was used to probe binding affinity to c-Src of
7long-chain fatty acids, such as myristate or palmitate. All NMR ex-
periments were recorded at 296 K on a Bruker DRX600 instrument. H
The c-Src concentration was 100 mol/l for each experiment, and (
myristate was present at 100 mol/l for the blue spectra in Figure p
6. In the case of unphosphorylated c-Src, experiments with 500 s
mol/l myristate or 500 mol/l palmitate were also carried out and B
did not yield chemical shift changes either. All spectra were ana- H
lyzed using XWinNMR. m
t
Supplemental Data
H
Supplemental data, including an additional figure, are available at
c
http://www.structure.org/cgi/content/full/13/6/861/DC1/.
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